Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908-916).

Original languageEnglish
Pages (from-to)881-882
Number of pages2
JournalNature medicine
Issue number8
StatePublished - Aug 2006


Dive into the research topics of 'Targeted cancer therapeutics: The heartbreak of success'. Together they form a unique fingerprint.

Cite this